Polylacticcoglycolic acid (PLGA) 50:50 and Eudragit RS 100 nanoparticles entrapping glipizide along with excipients were prepared using single emulsion solvent evaporation method. The objective was to develop single oral dose glipizide nano particles for reducing blood sugar level in diabetes induced experimental animals. Incorporation of Polyethylene glycol (PEG) (0.5%), Hydroxypropyl methylcellulose (HPMC) (0.5%) and
Introduction
Polymer like PLGA and Eudragit nanoparticles have diverse biomedical application particularly in the area of diagnosis, tissue engineering and as drug delivery agents 17 . To date, several polymeric micro and nanoparticles have been used for the delivery of drugs and therapeutic proteins 810 . Two major problems hinder the biological application of polymeric nanoparticles based delivery system. One is the optimal formulation with appreciable load of the drug with desired sustained release profile 11 . The other is the toxicity of nano particulate system 12 . The major toxicological concern with respect to nanomaterials particularly to be redox active 1315 and some particles transport across mammalian cell membranes and especially into mitochondria 16 . It is thus imperative to evaluate the toxicological parameters associated with nanoparticles before evaluating their therapeutic potential for drug/biomolecules delivery.
Glipizide is an oral hypoglycemic agent, which is a commonly prescribed drug for the treatment of type II diabetes mellitus 17 . It is a weak acid (pK a = 5.9), practically insoluble in water and acidic environment but highly permeable according to biopharmaceutical classification system (BSC) 18 . Oral absorption is uniform, rapid and complete with a bioavailability of 100 % and the elimination half life is 24 hours 18 .
Glipizide have a short biological half life (3.4 ± 0.7 hour) requiring it to be administered in 23 doses of 2.5 to 10 mg per day 19 . As the glipizide have a short biological half life Though a number of multiparticulate systems have been proposed for per oral controlled delivery of glipizide, most of them are polymeric drug delivery systems 20, 21 and the major problem is the slow release of glipizide from the polymeric matrix due to its hydrophobic nature. To the best of our knowledge the role of such excipients (PEG, HPMC and Tween 20) on release of small molecular hydrophobic drugs like glipizide from polymeric nanoparticles system has not addressed so far in the literature.
Due to the hydrophobic nature of glipizide, more hydrophilic excipients (PEG, HPMC and Tween 20) were used during formulation. During particle preparation, co encapsulation of glipizide with PEG, HPMC and Tween 20 the hydrophilic group is exposed towards the external aqueous phase which improves the hydrophilicity of the polymeric nanoparticles and enhance the release of glipizide from the polymeric nanoparticles. Additionally, PEG and HPMC are polymeric osmoagents which have the ability to improve the release of drug osmotically 22 .
The objective of the present investigation was to improve the release of entrapped glipizide from the PLGA 50:50 and Eudragit RS 100 nanoparticles by incorporation of polymeric excipients. The in vitro cytotoxicity of these nanoparticles was evaluated in SW 480 adenocarcinoma human cell line. Efficacy of polymeric formulations was evaluated in vivo in terms of lowering of blood glucose level in Wistar rats through oral administration.
Materials and methods

Materials
Poly LactidecoGlycolide (PLGA) [ 
Preparation of Nanoparticles
PLGA (50:50) and Eudragit RS 100 nanoparticles entrapping glipizide were prepared by a solvent evaporation method 23 . This involves preparation of oil in water (O/W) emulsion between the glipizide and polymer solution in dichloromethane (DCM) and an external aqueous phase (EAP) containing PVA and sucrose. The emulsion was stirred over night to evaporate residual DCM. Sonication at 40 % duty cycle for 3 minutes was used to prepare the emulsion. After complete evaporation of excess DCM, the particulate suspension was centrifuged at 15000 rpm for 20 minutes and washed thrice with Milli Q water for complete removal of excess PVA. The samples were lyophilized to produce a free flowing powder. Initially, the phase volume ratio and (sonication) energy input were standardized to produce the desired size particle (~ 200 nm). To improve the release profile of glipizide from the polymeric nanoparticles, three different polymeric excipients were incorporated in the organic phase during preparation of the nanoparticles. Type and concentration of excipients were varied during formulation keeping constant phase volume ratio and energy input. Detailed compositions of different formulations used for particle preparation are given in table 1.
Characterization of PLGA and Eudragit RS 100 nanoparticles
The size distributions of the glipizide loaded nanoparticles were analyzed using a particle size analyzer (Master sizer, Malvern instruments, UK). For a typical experiment, about 20 mg of nanoparticles was suspended in 5 ml of Mill Q water and analyzed with an obscuration index (measurement of the amount of light lost due to the introduction of the sample into the light path) ranging from 5 to 10 %. Zeta potential of the different formulations was estimated by a Zeta sizer (Malvern Instruments, UK). 
Entrapment efficiency of glipizide
Theoretical load
Practical load X 100
Cytotoxicity assay
The Alamar blue (AB) assay was carried out for quantitative measurement of cell viability 24, 25 . Cells were plated at a seeding density of 1 x 10 5 cells/ml for the 24 hour test, 6 x 10 4 cells/ml for the 48 hour test, 4 x 10 4 cells/ml for the 72 hour and
In vitro drug release study
In vitro release of glipizide nanoparticles were carried out at 37°C. Approximately 10 mg nanoparticles were suspended in 1 ml of phosphate buffer saline (pH 7.4) taken in a 1.6 ml microfuge tube and placed in an incubator shaker for the period of study (37°C, 200 rpm). Drug samples were collected at different time intervals after centrifugation at 13,000 rpm for 10 minutes and the amount of drug released in the supernatant was estimated by UV/Visible spectroscopy (at 276 nm) method 36 . The pellet was reconstituted, resuspended in 1 ml of fresh phosphate buffer saline (pH 7.4) and kept in a shaker for further sampling.
In vivo studies
Animals were maintained according to the guidelines established by the Institute of Animal Ethics Committee (IAEC) of the National Institute of Immunology, New Delhi.
The efficacy of glipizide loaded nanoparticles of different formulation were evaluated in female outbreed Wistar rats (n = 6), weighing between 200 g to 250 g. Glipizide loaded PLGA, and Eudragit RS 100 nanoparticles were suspended in Milli Q water and administered orally with the help of an oral cannula. Care was taken to ensure that the particle suspension entered through the esophagus. Animals were divided into 6 groups of six animals and were provided with standard diet and water ad libitum. Group I served as control, Group II were given a suspension of glipizide loaded PLGA nanoparticles (Formulation A1) orally at a dose level of 800 μg/Kg body weight, Group III were given suspension of glipizide loaded PLGA nanoparticles (Formulation A5) orally at a dose level of 800 μg/Kg body weight, Group IV were given suspension of glipizide loaded Eudragit RS 100 nanoparticles (Formulation B1) orally at a dose level of 800 μg/Kg body weight. Group V were given suspension of glipizide loaded Eudragit RS 100 nanoparticles (Formulation B5) orally at a dose level of 800 μg/Kg body weight.
Group VI were given suspension of standard glipizide orally at a dose level of 800 μg/Kg body weight. The blood samples were withdrawn from the retroorbital plexus of each rat pretreatment and at 1, 2, 4, 6, 12, and 24 hours posttreatment. The serum was separated and stored at -20 ° C for estimation of glucose level. Glucose levels in the serum were estimated by the Glucose Oxidase Peroxidase method 26 .
Statistical analysis
Statistical analyses were carried out using oneway analyses of variance (ANOVA) followed by Dunnett's multiple comparison tests. Statistical significance was accepted at P ≤ 0.05 for all tests. Cytotoxicity was expressed as mean percentage inhibition relative to the unexposed control ± standard deviation (SD). PLGA nanoparticles are more stable in the gastrointestinal tract than other colloidal carriers, such as liposomes, and the use of polymeric materials enable the modulation of physicochemical characteristics (e.g. hydrophobicity, zeta potential), drug release properties (e.g. delayed, prolonged, triggered), and biological behavior (e.g. targeting, bioadhesion, improved cellular uptake) of the nanoparticles 27 . From previous studies it was concluded that by adjusting the phase volume ratio (Organic phase and External aqueous phase) and energy input in terms of sonication/homogenization, different size polymeric particles can be generated 23, 26 . In this study the sonication time (40 % duty cycle for 3 minute) was increased and the phase volume ratio adjusted ( 26, 28, 29 . This suggested that these excipients mostly stabilize the aqueous/organic emulsion droplet during primary emulsification step of particle formulation. As primary emulsion stability controls the features of the polymer particles, these excipients helped in stable particle formulation.
Results and Discussion
Characterization of glipizide loaded PLGA and Eudragit RS 100 Nanoparticles
The zeta potential of plain PLGA particles was nearly 7 mV and upon addition of different surfactants this value decreased to 15 mV which was an indication of an improvement of the colloidal stability and a reduction in the tendency of the nanoparticles to agglomerates. However, the zeta potential of plain Eudragit RS 100 nanoparticles was 23 mV resulting in an almost stable colloidal suspension. Upon addition of surfactant during particle preparation, the zeta potential value slightly decreased, indicating aggregation of nanoparticles.
Zeta potential is the degree of repulsion between adjacent, similarly charged particles. After addition of nonionic surfactants to nanoparticle formulation the change of zeta potential occur due to change in force of attraction/repulsion between the particles. It has also been reported that zeta potential of PLGA and PEGPLGA nanoparticles is differ because of the PEG concentration reduces the overall negative surface charge 30 and also hydrophobic interaction has important role in the change of zeta potential with the nonionic surfactant 31 .
In vitro release of glipizide from polymeric nanoparticles
Glipizide released from nanoparticles at different time intervals was analyzed spectroscopically. The in vitro release of glipizide from PLGA particles was faster than the Eudragit RS 100 nanoparticles without any burst release in the initial 30 minutes, after which, sustained release of glipizide was observed (Figure 2 and 3 Tween 20 is relatively nontoxic 32 and is used as an emulsifier during particle preparation for improving the stability of emulsion and as a surfactant in a number of domestic, scientific, and pharmacological applications. The release profile can also be controlled by altering the pH of PLGA film by incorporation of basic amines (ammonium acetate/magnesium acetate) which can change the rate of degradation of polymer as results improve the release of drugs from the polymer particles 33 .
Incorporation of stabilizers not only helped in improved entrapment of the drug in the particles but also helped in continuous release of the drug from the particles.
In vitro cytotoxicity study of PLGA and Eudragit nanoparticles
Cytotoxicity of the PLGA and Eudragit RS 100 nanoparticles was studied in the SW480 cells, a primary adenocarcinoma cell line of colon. As these nanoparticles are proposed for the oral delivery of antidiabetic drugs like glipizide, the cell line was chosen to evaluate the cytocompatibility to the intestinal model. The assay was carried out by using alamar blue (AB), a watersoluble dye that has been previously used for quantifying in vitro viability of various cells 14, 15 . When added to cell cultures, the oxidized form of the AB enters the cytosol and is converted to the reduced form by mitochondrial enzyme activity by accepting electrons from NADPH, FADH, FMNH, and NADH as well as from the cytochromes. This redox reaction is accompanied by a shift in colour of the culture medium from indigo blue to fluorescent pink, which can be easily measured by colorimetric or fluorometric analysis 14 . No significant cytotoxicity was observed at a concentration range of 12.5 to 500 µg/ml (Figure 4 and 5) . In recent days, it was given most attention to the nanomaterials toxicity to human health, so it is important to understand the adverse toxicology of these polymeric nanoparticles.
Particles less than 1000 nm was easily cross the cell membrane and follow different kinetic within the cells according to the surface functional group. In our recent study of PNIAPM nanoparticles with ~ 70nm particles, although internalized and localized in lysosomes, did not show any toxicological response to HaCaT (keratinocyte cells) and SW 480 (Primary adenocarcinoma cells) 15 . Similarly, both PLGA and Eudragit RS 100 nanoparticles of ~ 200 nm size did not produce any adverse toxicological response to the SW 480 cells at exposure concentration between 12.5 to 500 µg/ml, as result shows excellent biocompatibility to SW 480 cells in vitro.
In vivo study of glipizide loaded PLGA and Eudragit RS 100 nanoparticles
The efficacy of the glipizide loaded PLGA and Eudragit RS 100 nanoparticles was evaluated in female outbreed Wistar rats at doses of 800 μg/Kg body weight.
Formulation A1, A5, B1 and B5 were selected for testing in vivo as the in vitro release of glipizide from these formulations was found to be better than the other formulations.
It was observed that all the formulations (A1, A5, B1 and B5) reduced the blood glucose 
Conclusions
High entrapment efficiency, biocompatibility of polymeric nanoparticles and continuous release of the entrapped drug are the most essential prerequisite for the development of Table 2 . Effect of different formulation on particle size, zeta potential and encapsulation efficiency. 
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